BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $207,000 | -15.9% | 3,835 | 0.0% | 0.02% | -11.1% |
| Q2 2022 | $246,000 | -17.2% | 3,835 | 0.0% | 0.02% | -5.3% |
| Q1 2022 | $297,000 | -19.3% | 3,835 | -10.5% | 0.02% | -17.4% |
| Q4 2021 | $368,000 | +6.7% | 4,285 | 0.0% | 0.02% | -4.2% |
| Q3 2021 | $345,000 | 0.0% | 4,285 | 0.0% | 0.02% | 0.0% |
| Q2 2021 | $345,000 | -4.4% | 4,285 | 0.0% | 0.02% | -7.7% |
| Q1 2021 | $361,000 | +4.9% | 4,285 | 0.0% | 0.03% | -7.1% |
| Q4 2020 | $344,000 | -31.9% | 4,285 | -31.8% | 0.03% | -37.8% |
| Q3 2020 | $505,000 | -7.7% | 6,285 | -1.0% | 0.04% | -15.1% |
| Q2 2020 | $547,000 | +6.2% | 6,349 | 0.0% | 0.05% | -18.5% |
| Q1 2020 | $515,000 | -4.5% | 6,349 | -1.6% | 0.06% | +22.6% |
| Q4 2019 | $539,000 | -4.1% | 6,449 | +0.4% | 0.05% | -10.2% |
| Q3 2019 | $562,000 | +6.8% | 6,425 | 0.0% | 0.06% | +7.3% |
| Q2 2019 | $526,000 | +34.2% | 6,425 | +33.3% | 0.06% | +37.5% |
| Q1 2019 | $392,000 | +36.1% | 4,820 | +10.3% | 0.04% | +17.6% |
| Q4 2018 | $288,000 | -14.5% | 4,370 | 0.0% | 0.03% | -2.9% |
| Q3 2018 | $337,000 | -2.3% | 4,370 | -6.4% | 0.04% | -10.3% |
| Q2 2018 | $345,000 | +13.5% | 4,670 | 0.0% | 0.04% | +11.4% |
| Q1 2018 | $304,000 | +0.7% | 4,670 | 0.0% | 0.04% | 0.0% |
| Q4 2017 | $302,000 | +3.1% | 4,670 | 0.0% | 0.04% | -2.8% |
| Q3 2017 | $293,000 | +3.5% | 4,670 | 0.0% | 0.04% | 0.0% |
| Q2 2017 | $283,000 | +16.9% | 4,670 | 0.0% | 0.04% | +12.5% |
| Q1 2017 | $242,000 | -17.1% | 4,670 | +12.0% | 0.03% | -31.9% |
| Q2 2015 | $292,000 | +2.1% | 4,170 | 0.0% | 0.05% | +2.2% |
| Q1 2015 | $286,000 | -6.5% | 4,170 | 0.0% | 0.05% | -6.1% |
| Q4 2014 | $306,000 | +2.3% | 4,170 | 0.0% | 0.05% | -2.0% |
| Q3 2014 | $299,000 | -0.7% | 4,170 | 0.0% | 0.05% | -2.0% |
| Q2 2014 | $301,000 | -2.0% | 4,170 | 0.0% | 0.05% | -7.3% |
| Q1 2014 | $307,000 | +5.9% | 4,170 | 0.0% | 0.06% | +3.8% |
| Q4 2013 | $290,000 | +3.6% | 4,170 | -2.3% | 0.05% | -3.6% |
| Q3 2013 | $280,000 | -5.4% | 4,270 | 0.0% | 0.06% | -9.8% |
| Q2 2013 | $296,000 | – | 4,270 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |